Evaluation of Voriconazole Population Pharmacokinetics in Japanese Patients and Factors Influencing Prediction Accuracy: A Machine Learning Approach
Abstract
Voriconazole (VRCZ) exhibits highly variable pharmacokinetics. Although CYP2C19 poor metabolizers are common in Japan, routine genetic testing is rarely performed in daily clinical practice. Consequently, existing population pharmacokinetic (Pop-PK) models that lack genetic data require external validation in Japanese clinical settings. This study aimed to identify the most accurate nongenetic Pop-PK model for this population and elucidate the factors influencing prediction errors. We retrospectively analyzed 174 adult inpatients who received VRCZ within the first 14 d of therapy. Eight Pop-PK models were evaluated using prediction error metrics and specific clinical criteria. For the best-performing model, normalized prediction distribution error (NPDE) analysis was conducted. Subsequently, a classification and regression tree (CART) analysis with leave-one-out cross-validation (LOOCV) was performed to identify factors associated with prediction accuracy. Model H, incorporating the albumin-bilirubin (ALBI) score, performed best (relative root mean square error 2.97, criteria 33.91%, median prediction error (MDPE) -29.06%). However, NPDE analysis (mean 0.774, variance 2.394) revealed residual systematic underprediction and substantial unmodeled variability. CART analysis identified C-reactive protein (CRP) as the primary determinant of accuracy. While the best model (age, platelet count, serum creatinine, and CRP) achieved a training accuracy of 69.5%, internal validation via LOOCV yielded an accuracy of 56.9% and a multi-class area under the receiver operating characteristic curve of 0.568. While the ALBI-score-based Model H is the most accurate, predictions remain limited in high-inflammation states due to inherent stochastic variability. Stratifying patients by baseline CRP level is crucial for optimizing the initial VRCZ dosing.
Related
- Physiologically Based Pharmacokinetic Modeling of Venetoclax in Pediatric Acute Myeloid Leukemia: Food Effects, Age-Related Pharmacokinetics, and Voriconazole-Mediated Drug-Drug Interactions.
- The pharmacokinetics and pharmacogenomics of voriconazole in pediatric Saudi patients: advancing toward precision medicine.
- Development and Population-Based Prognostic Utility Assessment of an ICD-10-CM-Based Prediction Model to Identify Left Ventricular Systolic Dysfunction: Discrimination Performance and Population-Based Evaluation in 83,357 Patients with Acute Coronary Syndrome
- Population pharmacokinetic modeling of voriconazole based on real-world data for dosing regimen optimization
- CSF pharmacokinetics-pharmacodynamics of linezolid in critically brain injured patients, with or without central nervous system healthcare-associated infection. The PK-Pop-LCR Study: A Multicentre Pharmacokinetics and Pharmacodynamics Population Study
BibTeX
@article{uemura2026evaluation,
title = {{Evaluation of Voriconazole Population Pharmacokinetics in Japanese Patients and Factors Influencing Prediction Accuracy: A Machine Learning Approach}},
author = {Yumi Uemura and Toshiaki Komatsu and Airi Suzuki and Yuto Akamada and Katsuya Otori},
journal = {Biological and Pharmaceutical Bulletin},
year = {2026},
month = jul,
doi = {10.1248/bpb.b26-00183},
url = {https://www.jstage.jst.go.jp/article/bpb/49/7/49_b26-00183/_article},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Evaluation of Voriconazole Population Pharmacokinetics in Japanese Patients and Factors Influencing Prediction Accuracy: A Machine Learning Approach
AU - Yumi Uemura
AU - Toshiaki Komatsu
AU - Airi Suzuki
AU - Yuto Akamada
AU - Katsuya Otori
PY - 2026
DA - 2026/07/09
JO - Biological and Pharmaceutical Bulletin
DO - 10.1248/bpb.b26-00183
UR - https://www.jstage.jst.go.jp/article/bpb/49/7/49_b26-00183/_article
AB - Voriconazole (VRCZ) exhibits highly variable pharmacokinetics. Although CYP2C19 poor metabolizers are common in Japan, routine genetic testing is rarely performed in daily clinical practice. Consequently, existing population pharmacokinetic (Pop-PK) models that lack genetic data require external validation in Japanese clinical settings. This study aimed to identify the most accurate nongenetic Pop-PK model for this population and elucidate the factors influencing prediction errors. We retrospectively analyzed 174 adult inpatients who received VRCZ within the first 14 d of therapy. Eight Pop-PK models were evaluated using prediction error metrics and specific clinical criteria. For the best-performing model, normalized prediction distribution error (NPDE) analysis was conducted. Subsequently, a classification and regression tree (CART) analysis with leave-one-out cross-validation (LOOCV) was performed to identify factors associated with prediction accuracy. Model H, incorporating the albumin-bilirubin (ALBI) score, performed best (relative root mean square error 2.97, criteria 33.91%, median prediction error (MDPE) -29.06%). However, NPDE analysis (mean 0.774, variance 2.394) revealed residual systematic underprediction and substantial unmodeled variability. CART analysis identified C-reactive protein (CRP) as the primary determinant of accuracy. While the best model (age, platelet count, serum creatinine, and CRP) achieved a training accuracy of 69.5%, internal validation via LOOCV yielded an accuracy of 56.9% and a multi-class area under the receiver operating characteristic curve of 0.568. While the ALBI-score-based Model H is the most accurate, predictions remain limited in high-inflammation states due to inherent stochastic variability. Stratifying patients by baseline CRP level is crucial for optimizing the initial VRCZ dosing.
SN - 1347-5215
SN - 0918-6158
ER -